On August 15, the U.S. government announced the final prices of the first 10 drugs Medicare negotiated under the Inflation Reduction Act (IRA).

The prices negotiated are much lower than the listed price of the drug. Of the 10 drugs, 9 had negotiated prices reduced by at least 50%. The products with the largest price cuts were diabetes treatment drugs: Merck's Januvia dropped its price by 79% from $527 to $113 per month; Novo Nordisk's Fiasp for treating type 1 diabetes dropped its price by 76% from $495 to $119 per month; AstraZeneca's Farxiga dropped its price by 68%. Among the 10 drugs, the one with the smallest price cut was Johnson & Cancer Treatment Imbruvica, whose price dropped 38% from $14,934 to $9,139 per month. Johnson & Johnson is the only company with more than one drug on the list. Its self-exempt heavyweight product Stelara (ustekinumab) has reduced its price by 66%, and its blood thinner Xarelto (rivaroxaban) has reduced its price by 62%.